These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 8815427)

  • 21. Endogenous chelation of exogenous aluminum in renal patients--a factor in aluminum toxicity?
    Biomater Artif Cells Immobilization Biotechnol; 1991; 19(3):661-2. PubMed ID: 1760497
    [No Abstract]   [Full Text] [Related]  

  • 22. Prevention and treatment of aluminum intoxication in chronic renal failure.
    Simon P; Allain P; Ang KS; Cam G; Mauras Y
    Adv Nephrol Necker Hosp; 1985; 14():439-78. PubMed ID: 3919543
    [No Abstract]   [Full Text] [Related]  

  • 23. Aluminum binding to organic acids and plasma proteins. Implications for dialysis encephalopathy.
    Trapp GA
    J Environ Pathol Toxicol Oncol; 1985; 6(1):15-20. PubMed ID: 4067831
    [No Abstract]   [Full Text] [Related]  

  • 24. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
    Sheppard LN; Kontoghiorghes GJ
    Arzneimittelforschung; 1993 Jun; 43(6):659-63. PubMed ID: 8352819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma protein binding of drugs and adjustment of their dosing regimen in patients with chronic renal failure.
    Schück O
    Int J Clin Pharmacol Ther Toxicol; 1987 Sep; 25(9):476-8. PubMed ID: 3679618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of hemodialysis and the effects of certain displacing agents on plasma protein binding of sulfamethoxazole and sulfaphenazole in patients with chronic renal failure.
    Kawamura T; Yagi N; Sugawara H; Yamahata K; Takada M
    Chem Pharm Bull (Tokyo); 1980 Jan; 28(1):268-76. PubMed ID: 7363373
    [No Abstract]   [Full Text] [Related]  

  • 29. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
    Graf H; Stummvoll HK; Meisinger V
    Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methods for studying the binding of aluminum by serum protein.
    Rahman H; Skillen AW; Channon SM; Ward MK; Kerr DN
    Clin Chem; 1985 Dec; 31(12):1969-73. PubMed ID: 4064285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum binding of aluminum.
    King SW; Wills MR; Savory J
    Res Commun Chem Pathol Pharmacol; 1979 Oct; 26(1):161-9. PubMed ID: 515501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioaccumulations of aluminum and the effects of chelating agents on different organs of Cirrhinus mrigala.
    Sivakumar S; Khatiwada CP; Sivasubramanian J
    Environ Toxicol Pharmacol; 2012 Nov; 34(3):791-800. PubMed ID: 23063109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Determination of the plasma aluminum concentration of hemodialysis patients].
    Kuleva V; Petrov I; Antonov S; Kiriakov Z
    Vutr Boles; 1984; 23(2):51-5. PubMed ID: 6741112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of equilibrium gel filtration chromatography for the study of protein binding of aluminum in normal and uremic sera.
    Bertholf RL; Wills MR; Savory J
    Clin Physiol Biochem; 1985; 3(5):271-6. PubMed ID: 4053493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of aluminum removal between hemodialysis with polycarbonate low flux membrane and hemofiltration with polysulfone high flux membrane in end-stage renal failure patients.
    Klemm A; Sperschneider H; Winnefeld K; Günther K; Stein G
    Clin Nephrol; 1997 Feb; 47(2):133-4. PubMed ID: 9049466
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bone disorders in children with chronic renal insufficiency exposed to high ingestion of aluminum].
    Gordillo-Paniagua G; Valencia-Mayoral P; Mercado L; Medina-Mercado M
    Bol Med Hosp Infant Mex; 1990 May; 47(5):336-41. PubMed ID: 2390188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aluminum levels in children with chronic renal failure who consume low-phosphorus infant formula.
    Andreoli SP
    J Pediatr; 1990 Feb; 116(2):282-5. PubMed ID: 2299504
    [No Abstract]   [Full Text] [Related]  

  • 39. Aluminum toxicity.
    Berlyne GM; Yagil R
    Lancet; 1972 Jul; 2(7766):47. PubMed ID: 4113645
    [No Abstract]   [Full Text] [Related]  

  • 40. N-Arylamine derivatives of 3-hydroxy-4-pyridinones: solution studies and bioevaluation in view of Al-detoxification roles.
    Santos MA; Gil M; Marques S; Gano L; Chaves S
    Anal Bioanal Chem; 2005 Jan; 381(2):413-9. PubMed ID: 15455189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.